Adding methotrexate for blood cancers not controlled by current therapy
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial is testing whether adding a low dose of methotrexate (a medicine often used for arthritis) can help people with certain blood cancers (myelofibrosis, polycythemia vera, or essential thrombocythemia) whose current treatments are not controlling their symptoms or blood counts well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a confirmed diagnosis of one of these blood cancers: polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (MF), or MF that started from PV or ET
- You've been on a stable dose of your current treatment for at least 12 weeks, but you still have symptoms (like fatigue, itching, or spleen discomfort) or abnormal blood counts (high white blood cells, high platelets, or needing regular phlebotomies)
- Your organs are working well enough (liver, kidneys, and blood cell counts are within safe limits)
- You do not have serious heart, lung, liver, or infection problems, and you have not taken methotrexate before for another condition
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two oral medications, momelotinib and ruxolitinib, to see which works better for people with newly diagnosed myelofibrosis who also have low blood cell counts. You may be able to join if your spleen is enlarged and you haven't had prior treatment with certain drugs.
This study tests an experimental drug called revumenib, either alone or combined with a JAK inhibitor, for people with myelofibrosis that is still active despite standard treatment. The goal is to see if revumenib can better control symptoms, reduce spleen size, or improve blood counts.
This trial tests whether increasing your methotrexate dose or switching from pills to injections can better control active rheumatoid arthritis. It's for people already taking a stable, moderate dose of methotrexate but still having joint swelling and symptoms.
This trial tests a new drug called INCA036978 for people with a group of blood cancers called myeloproliferative neoplasms (MPNs), including myelofibrosis, polycythemia vera, and essential thrombocythemia. It aims to see if the drug is safe and works well.
This Phase 2 trial tests whether giving high-dose methotrexate into the bloodstream can help treat breast cancer that has spread to the thin lining covering the brain and spinal cord. It may help reduce cancer in the leptomeningeal (brain-lining) area and control symptoms.
This trial checks how well methotrexate is tolerated in people with primary central nervous system lymphoma. It aims to catch early signs of toxicity to help manage side effects better.
Hear when a new Myelofibrosis (MF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.